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Abstract
The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against
dengue, but recent findings indicate an elevated risk of severe disease among vaccinees
without prior dengue virus (DENV) exposure. The World Health Organization currently rec-
ommends CYD-TDV only for individuals with serological confirmation of past DENV expo-
sure. Our objective was to evaluate the potential health impact and cost-effectiveness of
vaccination following serological screening. To do so, we used an agent-based model to
simulate DENV transmission with and without vaccination over a 10-year timeframe. Across
a range of values for the proportion of vaccinees with prior DENV exposure, we projected
the proportion of symptomatic and hospitalized cases averted as a function of the sensitivity
and specificity of serological screening. Scenarios about the cost-effectiveness of screening
and vaccination were chosen to be representative of Brazil and the Philippines. We found
that public health impact depended primarily on sensitivity in high-transmission settings and
on specificity in low-transmission settings. Cost-effectiveness could be achievable from the
perspective of a public payer provided that sensitivity and the value of a disability-adjusted
life-year were both high, but only in high-transmission settings. Requirements for reducing
relative risk and achieving cost-effectiveness from an individual perspective were more
restricted, due to the fact that those who test negative pay for screening but receive no ben-
efit. Our results predict that cost-effectiveness could be achieved only in high-transmission
areas of dengue-endemic countries with a relatively high per capita GDP, such as Panama´
(13,680 USD), Brazil (8,649 USD), Me´xico (8,201 USD), or Thailand (5,807 USD). In conclu-
sion, vaccination with CYD-TDV following serological screening could have a positive
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impact in some high-transmission settings, provided that screening is highly specific (to min-
imize individual harm), at least moderately sensitive (to maximize population benefit), and
sufficiently inexpensive (depending on the setting).
Author summary
Among several viral diseases transmitted by Aedes aegypti mosquitoes, dengue imposes
the greatest and most persistent burden on global health. Efforts to curb its spread would
benefit greatly from the availability of an effective vaccine. Currently, the only licensed
dengue vaccine, known as CYD-TDV or by the brand name Dengvaxia, is only recom-
mended for use in people who are known to have been exposed to dengue virus in the
past. Because symptoms of dengue can range from severe to mild to imperceptible, using
clinical history alone to assess whether a person was previously exposed is unreliable.
Instead, serological assays, which measure a person’s immune response to dengue virus,
are necessary to confirm whether a person was previously exposed. Because serological
assays can be subject to substantial error, we used a simulation model to assess how
impactful CYD-TDV vaccination would be under different scenarios about the accuracy
of a serological assay and the intensity of transmission in a given area. We found that the
health impact and cost-effectiveness of CYD-TDV vaccination depended on the accuracy
of the serological assay, its cost, and the setting in which it is deployed.
Introduction
A safe and effective dengue vaccine could have a major public health impact, as dengue causes
approximately 9,000 deaths and between 50–100 million clinically apparent cases worldwide
every year [1,2] and has a growing geographic distribution [3]. The first licensed dengue vac-
cine, CYD-TDV (Dengvaxia), is a tetravalent, live-attenuated vaccine that was licensed in mul-
tiple countries after demonstrating efficacy against symptomatic disease in phase-III trials
[4,5]. Protection has been hypothesized to derive primarily from the vaccine functioning as a
“silent infection” [6]. Following their first natural infection subsequent to vaccination, this
mechanism would result in vaccinees with prior dengue virus (DENV) exposure bypassing the
elevated risk of severe disease typically associated with secondary infections. Modeling analyses
[6,7] indicated that vaccination of nine-year-old children with CYD-TDV could be cost-effec-
tive in populations in which the majority of vaccinees have prior DENV exposure.
The downside of this mode of protection is an elevated risk of severe disease in vaccinees
with no prior DENV exposure at the time of their first natural DENV infection [8]. Recent
findings [9] confirmed this hypothesis, leading to an abrupt end to CYD-TDV use in the Phil-
ippines [10] and a revision of the World Health Organization’s (WHO) Strategic Advisory
Group of Experts on Immunization recommendations in April 2018 on the use of the vaccine
[11]. Vaccination with CYD-TDV is now recommended only for individuals with known
prior DENV exposure [12–14]. Because DENV infection often results in asymptomatic infec-
tion or presents with mild, non-specific symptoms [15], an individual’s clinical history is a
poor indicator of prior exposure. Thus, serological screening must play a role in any path for-
ward for CYD-TDV or any other future dengue vaccines with similar characteristics. Reliable
inference of prior DENV exposure based on serological data can be extremely challenging,
however, due to cross-reactivity among DENV serotypes and among DENV and other flavivi-
ruses [16,17].
Impact and cost-effectiveness of dengue vaccination following screening for prior exposure
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To avoid elevating the risk of severe dengue by vaccinating a DENV-naïve individual, sero-
logical screening used to inform vaccination must have high specificity (i.e., probability that a
DENV-naïve individual tests seronegative). At the same time, high sensitivity (i.e., probability
that an individual with prior DENV exposure tests seropositive) is important for ensuring that
people who could benefit from the vaccine will receive it. The balance of benefits and harms
caused by vaccination with CYD-TDV following serological screening with a given sensitivity
and specificity must also be weighed against the economic benefits and costs of such a strategy.
Although a strategy of CYD-TDV vaccination following serological screening has been exam-
ined with mathematical modeling before [18,19], those analyses were restricted to a scenario
in which the screening assay had perfect sensitivity and specificity. In practice, imperfect sensi-
tivity and specificity [20], tradeoffs between sensitivity and specificity [21], and cost [22] all
merit consideration in analyses of serological screening in CYD-TDV vaccination programs.
We applied an agent-based model of DENV transmission to identify the conditions under
which a strategy of vaccination with CYD-TDV following serological screening (hereafter,
referred to together as “the intervention”) would have positive impacts on health and be cost-
effective. As with a previous study [7] involving this model and seven others, we focused our
analysis on a strategy of routine intervention applied to a single age of nine years old. From
both an individual and population perspective, we identified minimum requirements to
achieve positive health impact and cost-effectiveness as a function of sensitivity, specificity,
cost of serological screening, cost of vaccination, and prior DENV exposure among nine-year-
olds (PE9). We focused on cost scenarios representative of Brazil and the Philippines, which
have both licensed CYD-TDV but differ in terms of economic conditions.
Methods
Model description
Our agent-based model of DENV transmission was previously described elsewhere [23]. This
model has been previously used as part of a consortium of eight modeling groups to make pro-
jections of CYD-TDV impact in the absence of serological screening [7]. Despite differences
with the other models, our model showed general agreement on projections of vaccination
impact. In our model, humans and mosquitoes are represented by individual agents who inter-
act with each other through mosquito blood-feeding at the household scale. The model
assumes that transmission of any of the four DENV serotypes can occur whenever an infected
mosquito blood-feeds on a susceptible human or a susceptible mosquito blood-feeds on an
infected human. Infected humans acquire life-long immunity to the infecting serotype and
temporary immunity to other serotypes to which they have not been previously exposed. Sev-
eral model features are parameterized based on extensive data collection from Iquitos, Peru,
including fine-scale patterns of human mobility [24], the demographic composition of house-
holds [25], and the geographic arrangement of residential, commercial, and other buildings
[26]. Other model features were less well known a priori: the rate at which DENV was seeded
into the population, the probability of an infectious mosquito infecting a susceptible human
during blood-feeding, and the emergence rate of adult female mosquitoes. For a given simula-
tion, we parameterized these features of the model by selecting a combination of parameter
values that achieved a target value of the proportion of nine-year-olds with prior DENV expo-
sure after 40 years of simulation, or PE9, as described in S1 Appendix.
Vaccination following serological screening
The vaccine implemented in our simulations acted as a silent DENV infection in the recipient,
as has been assumed in previous CYD-TDV modeling assessments [6,7]. Because the vaccine
Impact and cost-effectiveness of dengue vaccination following screening for prior exposure
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is assumed to act as a silent infection, vaccination results in an elevated risk of severe disease
among DENV-naïve vaccinees experiencing their first natural DENV infection, because sec-
ondary infections are associated with the highest probabilities of symptomatic disease condi-
tional on infection and hospitalization conditional on symptomatic disease. In addition, we
assumed a period of temporary cross-immunity after vaccination that waned over time. The
level of protection and the waning period varied for individuals with and without previous
exposure to DENV. Death was assumed to occur among a small proportion (0.0078) of cases
of symptomatic disease. Because estimates of the rates of these outcomes are highly variable
across study settings [27], we calibrated our model such that its outputs matched the most
recent estimates of vaccine protection from clinical trials [9]. We did so by simulating a virtual
trial [28] similar to the trials across a range of values of ten model parameters (Table 1) using a
sequential importance sampling approach [29] and generalized additive models from the
‘mgcv’ [30] library in R[31], as described in S2 Appendix. The best-fit model showed agree-
ment with estimates of vaccine efficacy against symptomatic disease and hazard ratios for hos-
pitalization stratified by age and baseline serostatus (S2 Appendix).
Consistent with recently revised WHO recommendations [12], we simulated serological
screening immediately prior to vaccination with CYD-TDV. We focused on a strategy of rou-
tine vaccination in which a proportion of children underwent serological screening, and vacci-
nation in the event of a positive result, on their ninth birthday. One consequence of this
strategy was that intervention coverage (i.e., the proportion of children screened) represents
an upper limit on the proportion of vaccine-eligible children. Assuming that all vaccine-eligi-
ble children were vaccinated, the vaccination coverage (i.e., positive serological screening
result and subsequent vaccination) was related to intervention coverage by
coveragevaccination ¼ coverageintervention � SP9; ð1Þ
where SP9 is seropositivity among nine-year-olds and is defined as
SP9 ¼ PE9 � sensitivity þ ð1   PE9Þ � ð1   specif icityÞ: ð2Þ
Similar to other models of CYD-TDV, our default assumption was a three-dose schedule
with 100% compliance. In the event that compliance is lower, our results would be more perti-
nent to a scenario with a correspondingly higher coverage, as the effects of coverage and com-
pliance are interchangeable in this way.
Table 1. Parameters describing vaccine profile calibrated to CYD-TDV trial data [9]. Details of the calibration
procedure are described in S2 Appendix.
Parameter Estimate
Per-exposure protection from vaccination for seronegative vaccinees 0.321
Per-exposure protection from vaccination for seropositive vaccinees 0.516
Average duration of protection for seronegative vaccinees 426 days
Average duration of protection for seropositive vaccinees 258 days
Probability of symptoms conditional on infection (primary) 0.405
Probability of symptoms conditional on infection (secondary) 0.339
Probability of symptoms conditional on infection (post-secondary) 0.09
Probability of hospitalization conditional on symptoms (primary) 0.074
Probability of hospitalization conditional on symptoms (secondary) 0.376
Probability of hospitalization conditional on symptoms (post-secondary) 0.101
https://doi.org/10.1371/journal.pntd.0007482.t001
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Simulations of intervention impact
We performed 3,000 sets of simulations of intervention impact, with each simulation set
involving one simulation with the intervention and one without. These simulation sets used
the sobol function in the pomp library [32] in R [31] to evenly span a range of values of inter-
vention coverage (10–80%), PE9 (0.1–0.9), and sensitivity (0–1) and specificity (0–1) of sero-
logical screening. Each simulation lasted for 50 years, with the intervention being introduced
after the first 40 years. Every year thereafter, a proportion of nine-year-olds underwent sero-
logical screening for prior DENV exposure and were vaccinated if screening returned a posi-
tive result. Both simulations in each set were initiated with the same random number seed,
which allowed us to isolate the impact of the intervention to the greatest extent possible under
a stochastic, agent-based model. With each set of parameter values, we calculated the propor-
tion of cases averted over a 10-year period as
proportion of cases averted
¼
cumulative cases w=o intervention   cumulative cases w=intervention
cumulative cases w=o intervention
ð3Þ
for both symptomatic and hospitalized cases. To estimate the impact of the intervention from
the perspective of an individual who chose to undergo serological screening, we compared the
risk of individuals from the first cohort of nine-year-olds who underwent serological screening
with individuals from a comparable cohort of nine-year-olds who did not undergo serological
screening. These individuals were followed for 10 years after vaccination and came from the
same simulation. We calculated relative risk of symptomatic disease and hospitalization as
relative risk ¼
ðcumulative cases w=interventionÞ=ðpopulation w=interventionÞ
ðcumulative cases w=o interventionÞ=ðpopulation w=o interventionÞ
: ð4Þ
To extract average patterns from the highly stochastic outputs from 3,000 simulations of
our model and to interpolate across gaps in parameter space, we summarized simulation out-
puts with generalized additive models, as described in S3 Appendix. To assess the impact of
vaccination over a longer time frame, we also evaluated effects of vaccination from both popu-
lation and individual perspectives over 30 years. Results corresponding to parameter sets
beyond those shown here can be explored interactively online at http://denguevaccine.crc.nd.
edu.
Identifying conditions for positive impact
Our first goal was to quantify the health impact of vaccination with CYD-TDV following sero-
logical screening under different conditions. At the population level, we made projections of
the proportion of cases averted over a 10-year period, separately for symptomatic and severe
cases, under a range of values of intervention coverage, PE9, sensitivity, and specificity. From
the perspective of an individual who underwent serological screening, and vaccination in the
event of a positive result, we made projections of the relative risk of experiencing a symptom-
atic or hospitalized case as compared to someone who forewent serological screening alto-
gether. We examined this individual risk in aggregate and stratified by prior DENV exposure.
Identifying conditions for cost-effectiveness
Our second goal was to understand the conditions under which vaccination with CYD-TDV
following serological screening might be cost-effective. The intervention was deemed cost-
Impact and cost-effectiveness of dengue vaccination following screening for prior exposure
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effective if
costintervention < DALYs averted� costDALY þ symptomatic cases averted� costsymp
þ hospitalizations averted� costhospitalized þ deaths averted� costdeath;
ð5Þ
where costsymp and costhospitalized reflect costs of ambulatory care and inpatient hospital care
for symptomatic and hospitalized cases, respectively, and costdeath refers to the direct cost of
death, such as burial expenses and disruption to family income. DALYs refer to disability-
adjusted life years, which are years of healthy life lost to disease. We based calculations of
DALYs averted on three components: symptomatic cases averted and the DALYs associated
with a symptomatic case, hospitalized cases averted and the DALYs associated with a hospital-
ized case, and deaths averted and the average number of years of life lost for an individual in
our model with a dengue-associated death. The cost of a DALY, costDALY, was based on a
country’s gross domestic product (GDP) per capita, in line with WHO guidance [33]. An
intervention with costintervention satisfying Eq 5 was deemed “cost-effective” when costDALY = 3
x per capita GDP and “very cost-effective” when costDALY = 1 x per capita GDP. Our assump-
tions about the numerical values of costs in Brazil and the Philippines are based on previous
estimates used by Flasche et al. [7] and are detailed in Table 2. We applied a 3% annual dis-
counting rate to both costs and DALYs.
We took two approaches from the perspective of the cost of the intervention, which is
defined as
costintervention ¼ coverageintervention � costscreen þ coveragevaccination � costvac; ð6Þ
where costscreen is the unit cost of serological screening and costvac is the cost of fully vaccinat-
ing a single person. Our first approach involved seeking the threshold cost of serological
screening at which costs below that threshold would be cost-effective when combined with a
costvac of 69 USD, which we based on pricing information from the Philippines [34] as
explained in S4 Appendix. Our second approach involved determining whether a fixed cost-
screen of 10 USD (similar to a recent estimate of 9.25 USD in Vietnam [22]) would result in
cost-effectiveness under three different assumptions about costvac corresponding to three,
two, or one doses (69, 46, or 23 USD), assuming that any number of doses confers the same
degree of protection. The possibility that fewer than three doses may confer protection against
dengue has been suggested as a possibility but requires further investigation [35]. Under both
approaches, we examined how cost-effectiveness varied as a function of intervention coverage,
PE9, and the sensitivity and specificity of serological screening.
Aspects of our cost-effectiveness analysis also differed depending on the perspective of who
was paying for the intervention: either a public payer (e.g., government or healthcare provider)
Table 2. Assumed costs and DALYs associated with dengue illness.
Parameter Brazil Philippines
Public payer Individual Public Payer Individual
costsymp $60 [36] $140 [5,37] $20 [4,38] $20 [4,37]
costhospitalized $200 [36,37] $300 [5,37] $400 [5,38] $100 [5,37]
costdeath - $11,000 [7] - $3,000 [7]
Per capita GDP $8,649.95 [39] $2,951 [39]
DALYs of symptomatic cases 0.006 [40]
DALYs of hospitalized cases 0.02 [40]
DALYs of fatal cases 1 x years of life lost
https://doi.org/10.1371/journal.pntd.0007482.t002
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or an individual. Health benefits in terms of cases and deaths averted differ from these popula-
tion and individual perspectives, with the former being of interest to a public payer. Costs
from these perspectives were differentiated in two ways. First, we monetized the direct cost of
death, costdeath, from the individual perspective as one year of productivity lost, as previously
assumed by Flasche et al. [7], but we assumed no additional direct costs of fatal cases from the
public payer perspective. Both perspectives considered the cost of death associated with
DALYs due to premature death. Second, we assumed that ambulatory care and hospitalization
costs were different for the individual and the public payer. Specific assumptions about costs
from these perspectives are provided in Table 2.
Results
Conditions for positive health impact from a population perspective
The proportion of cases averted depended on the sensitivity and specificity of serological
screening in different ways for different values of PE9. In terms of symptomatic cases, the
intervention resulted in a positive impact under nearly all combinations of parameters in all
transmission settings. This was a consequence of the fact that calibration of our model to data
from CYD-TDV trials resulted in estimates of the probability of symptomatic disease that
decreased with each successive infection (Table 1).Thus, vaccinating more people, regardless
of serostatus, resulted in more symptomatic cases averted (Fig 1, top). Although a lower proba-
bility of symptomatic disease in secondary infections differs from other modeling studies
[6,7,41], it is consistent with calibration of our model to the most recent trial data [9]. In terms
of hospitalizations averted, the intervention resulted in a negative impact under approximately
half of the scenarios we examined. Specifically, impact was more positive in settings with
higher transmission and more negative in settings with lower transmission (Fig 1, bottom).
With respect to screening properties, sensitivity was the dominant factor in high-transmission
settings, and specificity was the dominant factor in low-transmission settings. For both
Fig 1. Cumulative proportion of cases averted (colors) over a 10-year period (top: symptomatic, bottom: hospitalized) as a function of the sensitivity (y-axis)
and specificity (x-axis) of serological screening. Each column shows results for a given transmission setting, defined by the proportion of nine-year-olds with previous
DENV exposure, PE9. Relationships at lower values of PE9 were less smooth, due to a larger influence of stochasticity and more uncertainty in these transmission
settings (S2 Fig). The strategy of vaccination without screening is represented in the top-left corner of each heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g001
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symptomatic and hospitalized cases, relationships at lower values of PE9 were less smooth,
due to a larger influence of stochasticity and more uncertainty in these transmission settings
(S2 Fig).
The primary explanation for the positive relationship between screening sensitivity and
cases averted in the highest PE9 setting (0.9) is that vaccination coverage depended almost
exclusively on sensitivity and very little on specificity (S1 Fig). From a population perspective,
achieving high coverage in a high-PE9 setting appeared ideal, although it also appeared that
high specificity had benefits in high-transmission settings by increasing the proportion of hos-
pitalized cases averted (11% for sensitivity = 1, specificity = 1) beyond levels achievable by high
vaccination coverage alone (9% for sensitivity = 1, specificity = 0) (Fig 1, bottom right). At low
PE9, coverage was highest when specificity was low (S1 Fig), but that resulted in an increased
number of DENV-naïve vaccinees who then went on to experience symptomatic disease and
possibly hospitalization upon natural infection (Fig 1, bottom left). Thus, public health impact
was maximized at low PE9 when specificity was high (which minimized individual harm) and
sensitivity was also high (which increased coverage among the few who should have been
vaccinated).
Conditions for positive health impact from an individual perspective
From the perspective of a nine-year-old who underwent serological screening (and, in the
event of a positive result, vaccination), the relative risk of symptomatic disease was generally
reduced. Given that the vaccine reduces the hazard of symptomatic disease for both seroposi-
tive and seronegative individuals, relative risk of symptomatic disease lessened as the propor-
tion of vaccination coverage increased (Fig 2, top). As with population-level impacts, the
relative risk of hospitalization was reduced in medium- to high-transmission settings
(PE9�0.5) and depended on sensitivity and specificity in other settings (PE9<0.5) (Fig 2,
bottom).
Fig 2. Per capita relative risk (colors) of symptomatic (top) and hospitalized (bottom) disease over a 10-year horizon in the first cohort of children who are
screened, (and, in the event of a positive result, vaccinated) as a function of the sensitivity (y-axis) and specificity (x-axis) of serological screening. Each column
shows these results in a given transmission setting, defined by the proportion of nine-year-olds with previous DENV exposure, PE9. The strategy of vaccination without
screening is represented in the top-left corner of each heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g002
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Under a scenario of PE9 = 0.7, relative risk of hospitalization was reduced when sensitivity
was at least 0.4 or specificity was above 0.9. This reduction was mostly driven by sensitivity
when specificity was below 0.8, whereas specificity modulated risk as much as sensitivity for
values of specificity above 0.8. The greatest benefits occurred in high-transmission settings
(PE9 = 0.9) with high sensitivity (�0.9) and high specificity (�0.8), in which case relative risk
was as low as 0.4 (Fig 2, bottom right). In low-transmission settings (PE9<0.5), relative risk of
hospitalization was generally elevated, unless specificity was very high. Moreover, the reduc-
tion of risk in low-transmission settings was low, even with high specificity and sensitivity.
Even though greater sensitivity reduced relative risk for an average person undergoing serolog-
ical screening, from the point of view of a truly seronegative individual undergoing screening,
relative risk of hospitalization was always elevated unless specificity was perfect (S3 Fig, top).
In medium- to high-transmission settings (PE9�0.5), relative risk was 1.1 or less for specificity
values above 0.9, compared to relative risk higher than 1.3 under a scenario in which serologi-
cal screening resulted in all children being vaccinated (sensitivity = 1, specificity = 0).
Age of vaccination
Under an assumption of routine vaccination, age of vaccination modulated the population-
level benefits of vaccination in terms of hospitalizations averted (S4 Fig). In higher transmis-
sion settings, vaccination at younger ages resulted in increased benefits, given that a large pro-
portion of vaccinees had at least one infection at the time of vaccination (S4 Fig, top right). In
contrast, benefits of vaccination were higher in low-transmission settings when older children
were vaccinated. Vaccination in low-transmission settings appeared to have positive impacts
only when routine vaccination occurred in children 15 years of age or older and specificity was
high (S4 Fig, bottom left).
Conditions for cost-effectiveness from a public payer perspective
From a public payer perspective, and assuming a cost for a full three doses of vaccine of 69
USD, our results suggest that a strategy of vaccinating seropositive nine-year-olds would be
cost-effective only under limited circumstances. In simulations of medium-transmission set-
tings (PE9 = 0.5) and with a Brazil-like scenario about costs, vaccinating seropositive nine-
year-olds was cost-effective for high values of specificity (>0.8) and modest values of sensitiv-
ity (>0.3). In high-transmission settings (PE9� 0.7), cost-effectiveness depended on both sen-
sitivity and specificity, with the highest thresholds for cost-effectiveness found at sensitivity
and specificity above 0.8 (Fig 3, bottom right). In a high-transmission scenario (PE = 0.9), we
found that the threshold cost for serological screening (i.e., the maximum cost at which the
intervention could still be cost-effective) was around 45 USD. Under a Philippines-like sce-
nario about costs, vaccinating seropositive nine-year-olds was not cost-effective under any of
the scenarios that we considered (S5 Fig).
Our results showed that cost-effectiveness was possible under a somewhat broader range of
parameters when we considered lower costs of the vaccine and a fixed cost of serological
screening (10 USD). We found that reducing the cost of the vaccine to 46 USD (equivalent to
two doses, assuming that they provide the same protection as three) had little impact on which
parameter combinations (PE9, sensitivity, specificity) resulted in cost-effectiveness (S6 & S7
Figs). In contrast, reducing the cost of the vaccine to 23 USD (equivalent to one dose, assum-
ing that it provides the same protection as three) resulted in cost-effectiveness in high-trans-
mission settings (PE9� 0.7) under both the Brazil and Philippines scenarios about costs (Fig
4, S8 Fig).
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Conditions for cost-effectiveness from an individual perspective
From the perspective of the parent of a nine-year-old child considering serological screening,
our results suggest that the intervention would not be cost-effective in Brazil or the Philippines
(Figs 5 & S9). For both countries, low coverage (10%) had the effect of slightly increasing the
threshold cost of serological screening relative to a scenario with high coverage (80%), but not
enough to achieve cost-effectiveness under any parameters we considered for the Philippines
(S10 & S11 Figs). This is a result of there being more to gain by an individual opting for the
intervention when coverage is lower, due to lower indirect protection from others who are vac-
cinated. Lowering the number of doses to two (46 USD) did not improve cost-effectiveness for
the Brazil-like cost scenario (S12 Fig), although lowering to one dose (23 USD) and assuming
a cost of serological screening of 10 USD did (Fig 6, bottom). Cost-effectiveness under these
scenarios in moderate transmission settings (PE = 0.5) depended on high sensitivity (>0.9)
and moderate specificity (>0.5). In high-transmission settings (PE9�0.7), cost-effectiveness
was achieved for sensitivity values above 0.5 (Fig 6, bottom). None of the scenarios that we
considered were cost-effective under the Philippines-like cost scenario (S13 & S14 Figs).
Health impact and cost-effectiveness over a 30-year period
Over a 30-year period, the public health impacts of the intervention were more pronounced
than over a 10-year period (Figs S15 & 1). This was true for both positive impacts in high-
transmission settings and negative impacts in low-transmission settings. From an individual
perspective, the magnitude of relative risk differed very little over 10-year and 30-year periods
(Figs S16 & 2). From both public health and individual perspectives, positive impacts were
observed across a slightly wider range of sensitivity and specificity values (S15 & S16 Figs).
Cost-effectiveness also increased from both of these perspectives, due to the fact that the cost
of the intervention was the same over both time periods (S17–S24 Figs).
Fig 3. Threshold cost of serological screening from a public payer perspective, assuming a vaccination cost of 69 USD and economic assumptions from Brazil.
Threshold costs are indicated by color as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(8,650 USD) in the top row and three times per capita GDP in the bottom row. The strategy of vaccination without screening is represented in the top-left corner of each
heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g003
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Discussion
Using a model consistent with seven others that informed the WHO’s initial position on
CYD-TDV [7,42] but updated with the latest clinical trial data [9], we assessed the potential
health impact and cost-effectiveness of the recent WHO recommendation [12] for vaccination
with CYD-TDV following serological screening. In some respects, our projections were similar
Fig 4. Cost-effectiveness of the intervention from a public payer perspective, assuming one dose of vaccine (23 USD) and a fixed cost of serological screening (10
USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5 is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value
(columns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three times per capita GDP in the bottom row. The strategy of vaccination
without screening is represented in the top-left corner of each heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g004
Fig 5. Threshold cost of serological screening from an individual perspective, assuming a vaccination cost of 69 USD and economic assumptions from Brazil.
Threshold costs are indicated by color as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(8,650 USD) in the top row and three times per capita GDP in the bottom row. The strategy of vaccination without screening is represented in the top-left corner of each
heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g005
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to previous results about vaccination without serological screening; namely, positive public
health impacts in areas with high previous exposure [6,7]. In other respects, our results provide
new insights on issues unique to the context of the WHO’s pre-vaccination screening
recommendation.
First, our results show that high specificity is essential for reducing hospitalizations in low-
transmission settings but, at the same time, leads to fewer symptomatic cases averted. The lat-
ter effect resulted from our assumption that the probability of symptomatic disease is highest
in primary infections and decreases with each successive infection. Models that differ in this
assumption would likely reach different conclusions about this issue. Second, our results show
that sensitivity is important for achieving positive health impacts in high-transmission settings,
due to the fact that higher sensitivity increases population coverage in those settings. Sensitiv-
ity appears to be less important in low-transmission settings though, from both population
and individual perspectives. Third, from a public payer perspective, we conclude that cost-
effectiveness is unlikely except in countries with relatively high GDP and assuming low costs
of serological screening (10 USD) and vaccination (23 USD). Even then, cost-effectiveness
would be limited to areas with relatively high transmission intensity and to tests with relatively
high sensitivity. Fourth, conditions for cost-effectiveness from an individual perspective were
more limited than from a public payer perspective. In low-transmission settings or with a low-
sensitivity test in high-transmission settings, this results from the fact that the many who test
negative pay to get tested but receive no health benefit as a result.
Like other modeling assessments of interventions under consideration for implementation
[43–46], our study focused on offering general insights. As a consequence, we were only able
to explore a relatively limited range of scenarios about vaccine roll-out. In reality, CYD-TDV
could be deployed in a top-down manner by governments, purchased by individuals, or some
combination thereof, given that is licensed for use in individuals ranging in age from nine to
45 years. Nevertheless, certain aspects of our analysis may offer insights about a broader range
of scenarios. For example, some of our results about routine vaccination in nine-year-olds may
Fig 6. Cost-effectiveness of the intervention from an individual perspective, assuming one dose of vaccine (23 USD) and a fixed cost of serological screening (10
USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5 is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value
(columns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three times per capita GDP in the bottom row. The strategy of vaccination
without screening is represented in the top-left corner of each heatmap (sensitivity = 1, specificity = 0).
https://doi.org/10.1371/journal.pntd.0007482.g006
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apply under alternative scenarios if our parameter for prior exposure among nine-year-olds,
PE9, is interpreted more broadly as prior exposure among vaccine recipients on the whole, at
whatever age that might be. Such an extrapolation would appropriately mimic the level of prior
exposure among vaccinees, but it may not accurately reflect transmission intensity in a popula-
tion in which that level of prior exposure is achieved by a different age. Also, given that at youn-
ger ages our model underestimated the attack rates of hospitalization at 60 months, projections
of our model at these ages would potentially underestimate hospitalizations in seronegative
individuals and overestimate the cost-effectiveness of routine pre-vaccination screening strate-
gies. However, it is unlikely that individuals in that age range would ever be vaccinated, and
within the 9–16 age range for routine vaccination that we considered, results from simulations
involving routine vaccination in nine-year-olds appeared reasonably robust.
With respect to economic considerations, our results indicate that serological screening,
and vaccination in the event of a positive result, could be cost-effective only under certain cir-
cumstances. Assuming as others have [47–49] that decisions about cost-effectiveness are made
in reference to a multiplier between per capita GDP and costDALY, our results predict that
cost-effectiveness could be achieved only in high-transmission areas of dengue-endemic coun-
tries with a relatively high per capita GDP, such as Panama´ (13,680 USD), Brazil (8,649 USD),
Me´xico (8,201 USD), or Thailand (5,807 USD) [39]. In the event that CYD-TDV vaccination
is recommended in a country but remains unfunded, it is likely that coverage and impact will
be low, similar to varicella vaccines in Australia and Canada [50–52]. To the extent that access
to CYD-TDV becomes associated with the economic means to pay for serological screening
and vaccination, this could exacerbate socioeconomic disparities in dengue’s burden.
It is also important to note that our analysis of cost-effectiveness does not imply affordabil-
ity. Multiple studies have shown that interventions that have been deemed “very cost-effective”
have nonetheless not been implemented in low- and middle-income countries due to a variety
of factors, such as implications for spending on competing public health priorities [53–55].
Another approach to estimating costDALY is to refer to incremental cost-effectiveness ratios
(ICERs) from other interventions that could be displaced by CYD-TDV, such as vaccines
against rotavirus and human papillomavirus. These interventions have been shown to be very
cost-effective in settings comparable to Brazil and the Philippines, with ICERs below 2,000
[56,57]. Based on our results, none of the scenarios that we considered would result in cost-
effectiveness of CYD-TDV comparable to these interventions, given that that would have
required cost-effectiveness to be achieved with costDALY < 2,000 USD.
Although our analysis provides an indication of desirable characteristics of assays for sero-
logical screening, there is not yet an assay available that is simultaneously rapid, point-of-care,
low-cost, and both highly sensitive and specific [58]. Neutralization assays, for example, are
reasonably accurate but expensive and time-consuming, whereas assays such as IgG ELISAs
are faster and relatively inexpensive, but often far less accurate [20]. Given the tradeoffs
between the sensitivity and specificity of any assay, our results suggest that priority should be
placed on maximizing specificity. Doing so would minimize the potential risks associated with
vaccination of DENV-naïve individuals misclassified by an imperfectly-specific assay as having
been previously exposed. Achieving high specificity in determining DENV serostatus is com-
plicated by numerous sources of cross-reactivity, including prior exposure to or vaccination
against Japanese encephalitis, West Nile, yellow fever, or Zika viruses [16]. Because these fac-
tors affecting cross-reactivity are population-specific, any assay used to inform vaccination
with CYD-TDV should be calibrated to results from a highly specific assay (e.g., plaque-reduc-
tion neutralization tests) in a given population to maximize specificity [59]. Inevitably though,
maximizing specificity will come at the cost of decreased sensitivity [21] and, as we have
shown, reduced population-level benefits. By considering the full range of possible sensitivities
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and specificities, our results offer a quantitative basis for assessing the potential impact and
cost-effectiveness of any existing or future assay.
In theory, a highly effective, tetravalent dengue vaccine could have a substantial impact on
reducing dengue’s considerable burden, but that goal remains elusive for numerous reasons
[60]. In the absence of a single intervention that is highly effective across a wide range of con-
texts, interest continues to grow in determining how to best combine multiple interventions in
ways that are appropriate for a given local context [61]. Making that determination has become
increasingly challenging due to nuanced, yet highly consequential, issues associated with use
of CYD-TDV. Mathematical modeling analyses offer important capabilities for addressing this
challenge due to their ability to weigh complex tradeoffs among intervention properties, as
demonstrated here with respect to the sensitivity and specificity of serological screening, prior
DENV exposure among vaccinees, and intervention coverage and cost. In addition, by consid-
ering both individual and population perspectives, our analysis provides information that
could be informative for discourse about difficult ethical considerations surrounding the use
of CYD-TDV [62].
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S1 Fig. Relationship between the proportion of nine-year-olds with previous DENV expo-
sure (columns) and the proportion who screen positive and receive vaccination (colors).
This relationship depends on the sensitivity (y-axis) and specificity (x-axis) of serological
screening.
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S2 Fig. Width of the confidence interval of the cumulative proportion of cases averted
over a 30-year period (top row: symptomatic, bottom row: hospitalized) as a function of
the sensitivity (y-axis) and specificity (x-axis) of serological screening. Each column shows
these results in a given transmission setting, defined by PE9.
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S3 Fig. Per capita relative risk (colors) of hospitalization for individuals seronegative
(top) and seropositive (bottom) over a 10-year horizon in the first cohort of individuals eli-
gible for vaccination after a positive result from serological screening, as a function of the
sensitivity (y-axis) and specificity (x-axis) of serological screening. Each column shows
these results in a given transmission setting, defined by the proportion of nine-year-olds with
previous DENV exposure, PE9.
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S4 Fig. Cumulative proportion of cases averted over a 10-year period for different ages of
routine vaccination.
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S5 Fig. Threshold cost of serological screening from a public payer perspective over a
10-year period, assuming a vaccination cost of 69 USD and economic assumptions from
the Philippines. Threshold costs are indicated by color as a function of sensitivity (y-axis),
specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(2,951 USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S6 Fig. Cost-effectiveness of the intervention over a 10-year period from a public payer
perspective, assuming two doses of vaccine (46 USD) and a fixed cost of serological screen-
ing (10 USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5 is
shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S7 Fig. Cost-effectiveness of the intervention over a 10-year period from a public payer
perspective, assuming two doses of vaccine (46 USD) and a fixed cost of serological screen-
ing (10 USD) under Philippines-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (2,951 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S8 Fig. Cost-effectiveness of the intervention over a 10-year period from a public payer
perspective, assuming one dose of vaccine (23 USD) and a fixed cost of serological screen-
ing (10 USD) under Philippines-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (2,951 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S9 Fig. Threshold cost of serological screening from an individual perspective over a
10-year period, assuming a vaccination cost of 69 USD and economic assumptions from
the Philippines. Threshold costs are indicated by color as a function of sensitivity (y-axis),
specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(2,951 USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S10 Fig. Cost-effectiveness of the intervention from an individual perspective at 10% cov-
erage, assuming one dose of vaccine (23 USD) and a fixed cost of serological screening (10
USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5 is shown in
green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (columns). The
value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three times per
capita GDP in the bottom row.
(JPEG)
S11 Fig. Cost-effectiveness of the intervention from an individual perspective at 10% cov-
erage, assuming one dose of vaccine (23 USD) and a fixed cost of serological screening (10
USD) under Philippines-like cost assumptions. Cost-effectiveness according to Eq 5 is
shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (2,951 USD) in the top row and three
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times per capita GDP in the bottom row.
(JPEG)
S12 Fig. Cost-effectiveness of the intervention over a 10-year period from an individual
perspective, assuming two doses of vaccine (46 USD) and a fixed cost of serological screen-
ing (10 USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5 is
shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S13 Fig. Cost-effectiveness of the intervention over a 10-year period from an individual
perspective, assuming two doses of vaccine (46 USD) and a fixed cost of serological screen-
ing (10 USD) under Philippines-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (2,951 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S14 Fig. Cost-effectiveness of the intervention over a 10-year period from an individual
perspective, assuming one dose of vaccine (23 USD) and a fixed cost of serological screen-
ing (10 USD) under Philippines-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (2,951 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S15 Fig. Cumulative proportion of cases averted (colors) over a 30-year period (top: symp-
tomatic, bottom: hospitalized) as a function of the sensitivity (y-axis) and specificity (x-
axis) of serological screening. Each column shows results for a given transmission setting,
defined by the proportion of nine-year-olds with previous DENV exposure, PE9.
(JPEG)
S16 Fig. Per capita relative risk (colors) of symptomatic (top) and hospitalized (bottom)
disease over a 30-year horizon in the first cohort eligible for vaccination after serological
screening with a positive result, as a function of the sensitivity (y-axis) and specificity (x-
axis) of serological screening. Each column shows these results in a given transmission set-
ting, defined by the proportion of nine-year-olds with previous DENV exposure, PE9.
(JPEG)
S17 Fig. Threshold cost of serological screening from a public payer perspective over a
30-year period, assuming a vaccination cost of 69 USD and economic assumptions from
Brazil. Threshold costs are indicated by color as a function of sensitivity (y-axis), specificity
(x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP (8,650
USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S18 Fig. Cost-effectiveness of the intervention from a public payer perspective over a
30-year period, assuming one dose of vaccine (23 USD) and a fixed cost of serological
screening (10 USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three
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times per capita GDP in the bottom row.
(JPEG)
S19 Fig. Threshold cost of serological screening from a public payer perspective over a
30-year period, assuming a vaccination cost of 69 USD and economic assumptions from
the Philippines. Threshold costs are indicated by color as a function of sensitivity (y-axis),
specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(8,650 USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S20 Fig. Cost-effectiveness of the intervention from a public payer perspective over a
30-year period, assuming one dose of vaccine (23 USD) and a fixed cost of serological
screening (10 USD) under the Philippines-like cost assumptions. Cost-effectiveness accord-
ing to Eq 5 is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9
value (columns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row
and three times per capita GDP in the bottom row.
(JPEG)
S21 Fig. Threshold cost of serological screening from an individual perspective over a
30-year period, assuming a vaccination cost of 69 USD and economic assumptions from
Brazil. Threshold costs are indicated by color as a function of sensitivity (y-axis), specificity
(x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP (8,650
USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S22 Fig. Cost-effectiveness of the intervention from an individual perspective over a
30-year period, assuming one dose of vaccine (23 USD) and a fixed cost of serological
screening (10 USD) under Brazil-like cost assumptions. Cost-effectiveness according to Eq 5
is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9 value (col-
umns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row and three
times per capita GDP in the bottom row.
(JPEG)
S23 Fig. Threshold cost of serological screening from an individual perspective over a
30-year period, assuming a vaccination cost of 69 USD and economic assumptions from
the Philippines. Threshold costs are indicated by color as a function of sensitivity (y-axis),
specificity (x-axis), and PE9 value (columns). The value of costDALY is equal to per capita GDP
(8,650 USD) in the top row and three times per capita GDP in the bottom row.
(JPEG)
S24 Fig. Cost-effectiveness of the intervention from an individual perspective over a
30-year period, assuming one dose of vaccine (23 USD) and a fixed cost of serological
screening (10 USD) under the Philippines-like cost assumptions. Cost-effectiveness accord-
ing to Eq 5 is shown in green as a function of sensitivity (y-axis), specificity (x-axis), and PE9
value (columns). The value of costDALY is equal to per capita GDP (8,650 USD) in the top row
and three times per capita GDP in the bottom row.
(JPEG)
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